

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (previously presented): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.
2. (previously presented): A crystal of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.
3. (previously presented): The crystal according to claim 2, which has X-ray powder diffraction spectrum shown in Fig 3.
4. (previously presented): The crystal according to claim 2, which has diffraction angle  $2\theta$  at 8.96, 12.70, 13.69, 14.98, 15.74, 16.38, 17.63, 18.98, 19.71, 20.49, 21.37, 22.26, 22.88, 23.76, 24.70, 25.79 and 26.57 on X-ray powder diffraction spectrum.
5. (previously presented): The crystal according to claim 2, which has infrared resonance spectrum shown in Fig. 4
6. (previously presented): The crystal according to claim 2, which has absorption of infrared resonance spectrum at 1652, 1595, 1549, 1220, 1168, 1141, 1115, 1034, 790, 766, 548, 533 and  $522\text{ cm}^{-1}$ .

7. (previously presented): A process for the preparation of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate, which comprises reacting 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine with methanesulfonic acid.

8. (currently amended): A pharmaceutical composition comprising the compound described in according to claim 1 as an active ingredient and a pharmaceutically acceptable carrier.

9. (currently amended): ~~A~~The pharmaceutical composition comprising 1% or more of at the crystal according to claim 2, as an active ingredient, described in claim 2 and a pharmaceutically acceptable carrier.

10. (canceled).

11. (currently amended): A method of treating a mammal suffering from a disease resulting from elevated activity of Corticotropin Releasing Factor (CRF) comprising administering to said mammal a therapeutically effective amount of The the pharmaceutical composition compound according to claim 81, which is a prevention and/or treatment agent of a CRF-mediated disease.

12. (currently amended): The ~~pharmaceutical composition according to method of~~ claim 11, wherein ~~the CRF-mediated said disease~~ resulting from elevated activity of Corticotropin Releasing Factor (CRF) is a neuropsychiatric disorder or a digestive system disease.

13. (currently amended): The ~~pharmaceutical composition according to method of~~ claim 12, wherein the neuropsychiatric disorder is a mood disorder, an anxiety disorder, a stress related disorder, an eating disorder, a symptom by psychotomimetic drug use and dependence, an organic mental disorder, schizophrenia or an attention-deficit hyperactivity disorder.

14. (currently amended): The ~~pharmaceutical composition according to method of~~ claim 12, wherein the digestive system disease is an irritable bowel syndrome or a stress-induced gastrointestinal disturbance.

15. (currently amended): The ~~pharmaceutical composition according to method of~~ claim 13, wherein the mood disorder is depression, single episode depression, recurrent depression, postpartum depression, child abuse induced depression, bipolar affective disorder or premenstrual dysphonic disorder.

16-19. (canceled).

20. (currently amended) A method for antagonizing the activity of CRF~~Corticotropin Releasing Factor (CRF)~~ in a mammal, ~~which comprises comprising~~ administering to said mammal an effective amount of ~~8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate to mammals~~the compound according to claim 1.

21-23. (canceled).

24. (new): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate which is superior in thermal stability.